GLIOBLASTOMA MULTIFORME OF BRAIN
Clinical trials for GLIOBLASTOMA MULTIFORME OF BRAIN explained in plain language.
Never miss a new study
Get alerted when new GLIOBLASTOMA MULTIFORME OF BRAIN trials appear
Sign up with your email to follow new studies for GLIOBLASTOMA MULTIFORME OF BRAIN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take on deadly brain tumors in new trial
Disease control ENROLLING_BY_INVITATIONThis early-stage trial tests a personalized treatment for glioblastoma, an aggressive brain cancer. It uses a patient's own immune cells, modified to better recognize and attack the tumor, combined with chemotherapy. The study aims to check safety and see if the treatment can shr…
Matched conditions: GLIOBLASTOMA MULTIFORME OF BRAIN
Phase: PHASE1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated May 26, 2026 10:10 UTC
-
New CAR T-Cell therapy targets Hard-to-Treat brain tumors
Disease control OngoingThis early-stage study tests a new treatment called CHM-1101 for people with a fast-growing brain cancer (glioblastoma) that has returned or worsened. The therapy uses specially engineered immune cells (CAR T-cells) designed to find and attack cancer cells carrying a marker calle…
Matched conditions: GLIOBLASTOMA MULTIFORME OF BRAIN
Phase: PHASE1 • Sponsor: Chimeric Therapeutics • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New drug shows promise in hitting Hard-to-Treat brain cancers
Disease control OngoingThis study tests a drug called niraparib in people with two types of brain tumors: newly diagnosed glioblastoma and recurrent IDH-mutant glioma with ATRX loss. The goal is to see if the drug reaches the tumor and slows its growth. Up to 42 participants will receive niraparib befo…
Matched conditions: GLIOBLASTOMA MULTIFORME OF BRAIN
Phase: EARLY_PHASE1 • Sponsor: Nader Sanai • Aim: Disease control
Last updated May 15, 2026 11:55 UTC